PureTech Founded Entity Vedanta Biosciences Receives Fast Tr

VE303 receives Fast Track designation for prevention of recurrent C. difficile infection ahead of global pivotal Phase 3 study


Exploratory analyses from the VE303 Phase 2 CONSORTIUM study identify... | May 9, 2023

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Chicago , Illinois , United States , American , Jeffreyl Silber , Rajita Menon , Human Services , Biomedical Advanced Research , Puretech Health , American Gastroenterological Association , American Society For Gastrointestinal Endoscopy , Department Of Health , Society For Surgery Of The Alimentary Tract , Twitter , Development Authority , University Of Massachusetts Medical School , Nasdaq , Sinai School Of Medicine , Drug Administration , Administration For Strategic Preparedness , Founded Entity , Vedanta Biosciences , Fast Track , Digestive Disease Week , Biosciences Receives Fast Track Designation , Presents Phase , Digestive Disease , Chief Medical Officer , Massachusetts Medical School , Sinai School , Strategic Preparedness , Orphan Drug Designation , Fast Track Designation , Disease Week , American Association , Liver Diseases , American Society , Gastrointestinal Endoscopy , Alimentary Tract , Founded Entities , Puretech Health Plc Stock Exchange , News , Information , Press Release , E303 , Eceives , Mast , Track , Resignation , Or , Prevention , F , Recurrent , Difficile , Infection , Head , Lobal , Pivotal , Hase , , Analyses , Rom , The , Consortium , Tudy Prtc Gb00by2z0h74 ,